Evidence map›Paper›PMID 32373555›Full record

ArticleFrontiers in cellular and infection microbiology2020

A New Hope for CD56

Catherine S Forconi, Cliff I Oduor, Peter O Oluoch, John M Ong'echa, Christian Münz, Jeffrey A Bailey, Ann M Moormann

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Immune dysfunction in Alzheimer disease.Nature reviews. Neuroscience · 2026
    Review
  6. Cytotoxic and Immunomodulatory Effects ofInternational journal of molecular sciences · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Catherine S ForconiDivision of Infectious Diseases, Department of Medicine, University of Massachusetts, Worcester, MA, United States.
Cliff I OduorDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI, United States.
Peter O OluochDivision of Infectious Diseases, Department of Medicine, University of Massachusetts, Worcester, MA, United States.
John M Ong'echaCenter for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Christian MünzLaboratory of Viral Immunology, Experimental Immunology Institute, University of Zurich, Zurich, Switzerland.
Jeffrey A BaileyDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI, United States.
Ann M MoormannDivision of Infectious Diseases, Department of Medicine, University of Massachusetts, Worcester, MA, United States.
Brown University · USKenya Medical Research Institute · KEUniversity of Massachusetts Chan Medical School · USUniversity of Zurich · CH

Funding

Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphomaR01CA189806 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MOORMANN, ANN M · 2014 to 2024
$5.7M
T Cell Immunity in Endemic Burkitt LymphomaR01CA134051 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MOORMANN, ANN M · 2008 to 2012
$2.3M
NCI NIH HHS R01 CA134051NCI NIH HHS R01 CA189806
6 · The paper itself

Abstract

Natural Killer (NK) cells play an essential role in antiviral and anti-tumoral immune responses. In peripheral blood, NK cells are commonly classified into two major subsets: CD56

Indexed as

Killer Cells, NaturalReceptors, IgGCD56 AntigenChildChronic DiseaseFlow CytometryHumansImmunotherapySignaling Lymphocytic Activation Molecule FamilyCD56 AntigenCD84 protein, humanReceptors, IgGSignaling Lymphocytic Activation Molecule FamilyCD56negCD16pos subsetendemic Burkitt lymphomaepstein-barr virusmalarianatural killer cellstranscription profile

Identifiers

PMID32373555
PMCPMC7186373
OpenAlexW3020284273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.